AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Biotechnology & Medical Research

Delayed Nyse Other stock markets 03:04:02 2024-05-13 pm EDT			5-day change	1st Jan Change
0.4192 ^USD	+4.80%		-0.19%	-4.71%

Apr. 29	AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	MT
Apr. 10	AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	CI

AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 31, 2023 at 04:43 pm EDT

AIM ImmunoTech Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 0.141 million compared to USD 0.135 million a year ago. Net loss was USD 19.45 million compared to USD 19.13 million a year ago.

Basic loss per share from continuing operations was USD 0.4 compared to USD 0.4 a year ago.

Latest news about AIM ImmunoTech Inc.

AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	Apr. 29	MT
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10	CI
Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024	Apr. 02
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Transcript : AIM ImmunoTech Inc. - Special Call	Mar. 20
AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding	Feb. 19	CI
AIM ImmunoTech Inc. announced that it has received $2.5 million in funding	Feb. 15	CI
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Feb. 08	CI
AIM ImmunoTech Says First Subject Enrolled in Phase 1b/2 Study of Pancreatic Cancer Combination Therapy	Jan. 22	MT
Declaration of Voting Results by AIM ImmunoTech	Jan. 10	CI
Transcript : AIM ImmunoTech Inc. - Pre Recorded Special Call	Jan. 09
Kellner Group Issues a Statement to the Shareholders	Jan. 03	CI
Sector Update: Health Care	Dec. 29	MT
AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	Dec. 29	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 29	MT
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board?s Determination that Activist Group?s Nominations Are Invalid	Dec. 29	CI
AIM ImmunoTech Provides Update Regarding Annual Meeting	Nov. 28	CI
AIM ImmunoTech Gets US Patents for Ampligen Cancer, ME/CFS Treatment Methods	Nov. 27	MT
AIM ImmunoTech Treats Last Participant in Phase 2 Study of Ampligen for Potential Treatment of Post-COVID Fatigue	Nov. 21	MT
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Nov. 21	CI
AIM ImmunoTech Mails Letter to its Shareholders	Nov. 20	CI
Transcript : AIM ImmunoTech Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
AIM ImmunoTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen	Nov. 14	CI

Chart AIM ImmunoTech Inc.

Duration

Period

More charts

Company Profile

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for AIM ImmunoTech Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4 USD

Average target price

3.5 USD

Spread / Average Target

+775.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AIM IMMUNOTECH INC.	-4.71%	19.96M
VERTEX PHARMACEUTICALS INCORPORATED	+5.30%	109B
REGENERON PHARMACEUTICALS, INC.	+11.37%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.08%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.36%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+2.93%	13.76B
SAREPTA THERAPEUTICS, INC.	+35.85%	12.46B

Bio Therapeutic Drugs